Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 5 points (0.0%) at 16,485 as of Friday, Dec. 27, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,370 issues advancing vs. 1,569 declining with 149 unchanged. The Drugs industry currently sits down 0.7% versus the S&P 500, which is unchanged. Top gainers within the industry include Shire ( SHPG), up 1.2%, GlaxoSmithKline ( GSK), up 1.0%, Novo Nordisk A/S ( NVO), up 0.8%, Amgen ( AMGN), up 0.6% and Celgene Corporation ( CELG), up 0.5%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Sanofi ( SNY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Sanofi is up $0.48 (0.9%) to $52.72 on light volume. Thus far, 304,731 shares of Sanofi exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $52.48-$52.92 after having opened the day at $52.63 as compared to the previous trading day's close of $52.24. Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $137.7 billion and is part of the health care sector. Shares are up 10.3% year to date as of the close of trading on Thursday. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.